Bufrolin

Modify Date: 2024-04-08 19:53:36

Bufrolin structure	Common Name	Bufrolin
	CAS Number	54867-56-0	Molecular Weight	356.33
	Density	1.478g/cm3	Boiling Point	609.6ºC at 760 mmHg
	Molecular Formula	C₁₈H₁₆N₂O₆	Melting Point	N/A
	MSDS	N/A	Flash Point	322.5ºC

Use of Bufrolin

Bufrolin is a Cromoglycate (histamine release inhibitor) analog and a high potency agonist of GPR35. Bufrolin promotes interactions between β-arrestin-2 and either human GPR35a or rat GPR35. Bufrolin also serves as antiallergic mast cell stabilizer and inhibit an anti-inflammatory response inducible by the internalization peptide. Bufrolin acts as an anti-inflammatory agent to be used in research of delivering pharmacol linked with internalization peptide[1][2][3].

Name	6-butyl-4,10-dioxo-1,7-dihydro-1,7-phenanthroline-2,8-dicarboxylic acid
Synonym	More Synonyms

Description	Bufrolin is a Cromoglycate (histamine release inhibitor) analog and a high potency agonist of GPR35. Bufrolin promotes interactions between β-arrestin-2 and either human GPR35a or rat GPR35. Bufrolin also serves as antiallergic mast cell stabilizer and inhibit an anti-inflammatory response inducible by the internalization peptide. Bufrolin acts as an anti-inflammatory agent to be used in research of delivering pharmacol linked with internalization peptide[1][2][3].
Related Catalog	Signaling Pathways >> Immunology/Inflammation >> Histamine Receptor Research Areas >> Inflammation/Immunology Signaling Pathways >> GPCR/G Protein >> Histamine Receptor
References	[1]. MacKenzie AE, et al. The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35. Mol Pharmacol. 2014 Jan;85(1):91-104. [2]. Church M K, et al. Comparison of sodium cromoglycate derivatives, anti-histamines and β-stimulants on histamine release from human lung in vitro[J]. International Archives of Allergy and Immunology, 1981, 66(Suppl. 1): 281-282. [3]. Tymianski M, et al. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory: United States, US8933013 B2. 2015-01-13.

Description

Related Catalog

Signaling Pathways >> Immunology/Inflammation >> Histamine Receptor

Research Areas >> Inflammation/Immunology

Signaling Pathways >> GPCR/G Protein >> Histamine Receptor

References

[1]. MacKenzie AE, et al. The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35. Mol Pharmacol. 2014 Jan;85(1):91-104.

[2]. Church M K, et al. Comparison of sodium cromoglycate derivatives, anti-histamines and β-stimulants on histamine release from human lung in vitro[J]. International Archives of Allergy and Immunology, 1981, 66(Suppl. 1): 281-282.

[3]. Tymianski M, et al. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory: United States, US8933013 B2. 2015-01-13.

Density	1.478g/cm3
Boiling Point	609.6ºC at 760 mmHg
Molecular Formula	C₁₈H₁₆N₂O₆
Molecular Weight	356.33
Flash Point	322.5ºC
Exact Mass	356.10100
PSA	140.84000
LogP	2.93320
Index of Refraction	1.648

HS Code	2933990090

HS Code	2933990090
Summary	2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Bufrolinum

6-butyl-1,4,7,10-tetrahydro-4,10-dioxo-1,7-phenathroline-2,8-dicarboxylic acid

Bufroline [INN-French]

6-butyl-4,10-dioxo-1,4,7,10-tetrahydro-[1,7]phenanthroline-2,8-dicarboxylic acid

Bufroline

6-butyl-4,10-dihydroxy-1,7-phenanthroline-2,8-dicarboxylic acid

Bufrolino

Bufrolin

Bufrolin

Use of Bufrolin

Names

Bufrolin Biological Activity

Chemical & Physical Properties

Safety Information

Customs

Synonyms